Diligence memo · auto-generated · as of July 2, 2026

Imago BioSciences, Inc.

Imago BioSciences, Inc. has raised $137M over 3 rounds; too few niche peers to rank its valuation yet.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Imago BioSciences, Inc. operates in Biotech / Pharma, based in San Carlos.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Imago BioSciences, Inc. has raised $137M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $80M on 2020-11-12.

Most recent recorded round closed around 2020-11-12.

Valuation (modeled)modeled

Provath models Imago BioSciences, Inc. at approximately $2.7B (range $254M–$6.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Historic cadence: a new round about every 24 months.

Last raise 5.6 yr ago; this sector typically re-raises about every 15 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 4.7× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 96% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 98% of those peers.

Closest niche peers: Life Biosciences LLC, BlueSphere Bio, Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.